Literature DB >> 20016922

Natural history of Charcot-Marie-Tooth 2: 2-year follow-up of muscle strength, walking ability and quality of life.

Luca Padua1, D Pareyson, I Aprile, T Cavallaro, D A Quattrone, N Rizzuto, G Vita, P Tonali, A Schenone.   

Abstract

Charcot-Marie-Tooth (CMT) disease is the most frequent inherited neuropathy, no therapies are available at the moment but clinical trials are ongoing. For that reason it is very important to know the natural history of the disease. We report the results of the natural history of clinical features and quality of life (QoL) in patients with CMT2. Twenty patients were enrolled. At recruitment and at follow-up (2 years), all patients underwent neurological evaluation, QoL and disability assessments. The study-end evaluation took place 20-28 months after the baseline evaluation. During the 2-year follow-up period, CMT2 patients showed a mild reduction of strength of distal muscles of upper limbs and proximal muscles of lower limbs, a worsening sensory function and a mild increase in walking disability. However, there was no relevant worsening of QoL, except for a mild deterioration of one mental health domain.

Entities:  

Mesh:

Year:  2009        PMID: 20016922     DOI: 10.1007/s10072-009-0202-z

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  18 in total

1.  131st ENMC international workshop: selection of outcome measures for peripheral neuropathy clinical trials 10-12 December 2004, Naarden, The Netherlands.

Authors:  I S J Merkies; G Lauria
Journal:  Neuromuscul Disord       Date:  2006-01-23       Impact factor: 4.296

2.  Perplexity about the use of the Charcot-Marie-Tooth Neuropathy Score in rehabilitation.

Authors:  P Vinci
Journal:  Eur J Phys Rehabil Med       Date:  2008-12       Impact factor: 2.874

3.  The use of Charcot-Marie-Tooth Neuropathy Score.

Authors:  L Padua; A Schenone; C Pazzaglia; D Pareyson
Journal:  Eur J Phys Rehabil Med       Date:  2009-06       Impact factor: 2.874

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

5.  136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands.

Authors:  M M Reilly; P de Jonghe; D Pareyson
Journal:  Neuromuscul Disord       Date:  2006-05-08       Impact factor: 4.296

6.  Charcot-Marie-Tooth disease impairs quality of life: why? And how do we improve it?

Authors:  Michael E Shy; Michael R Rose
Journal:  Neurology       Date:  2005-09-27       Impact factor: 9.910

7.  Reliability and validity of the CMT neuropathy score as a measure of disability.

Authors:  M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

Review 8.  Experimental therapeutics in hereditary neuropathies: the past, the present, and the future.

Authors:  David N Herrmann
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

9.  Motor and functional recovery after stroke: accuracy of physical therapists' predictions.

Authors:  N Korner-Bitensky; N Mayo; R Cabot; R Becker; H Coopersmith
Journal:  Arch Phys Med Rehabil       Date:  1989-02       Impact factor: 3.966

10.  A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27].

Authors:  Davide Pareyson; Angelo Schenone; Gian Maria Fabrizi; Lucio Santoro; Luca Padua; Aldo Quattrone; Giuseppe Vita; Franco Gemignani; Francesco Visioli; Alessandra Solari
Journal:  Pharmacol Res       Date:  2006-09-09       Impact factor: 7.658

View more
  9 in total

1.  Proximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseases.

Authors:  Richard D Dortch; Lindsey M Dethrage; John C Gore; Seth A Smith; Jun Li
Journal:  Neurology       Date:  2014-09-24       Impact factor: 9.910

2.  Management of Stress Urinary Incontinence With Pelvic Floor Muscle Training for a Woman With Charcot-Marie-Tooth Disease: A Case Report.

Authors:  Letícia A Ferreira; Fátima F Fitz; Márcia M Gimenez; Mayanni M P Matias; Maria A T Bortolini; Rodrigo A Castro
Journal:  J Chiropr Med       Date:  2022-06-06

3.  Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective.

Authors:  Nicholas E Johnson; Chad R Heatwole; Nuran Dilek; Janet Sowden; Callyn A Kirk; Denise Shereff; Michael E Shy; David N Herrmann
Journal:  Neuromuscul Disord       Date:  2014-06-27       Impact factor: 4.296

4.  The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.

Authors:  Nicholas E Johnson; Chad Heatwole; Peter Creigh; Michael P McDermott; Nuran Dilek; Man Hung; Jerry Bounsanga; Wan Tang; Michael E Shy; David N Herrmann
Journal:  Ann Neurol       Date:  2018-08-29       Impact factor: 10.422

5.  Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy.

Authors:  Lori Sames; Allison Moore; Renee Arnold; Sean Ekins
Journal:  F1000Res       Date:  2014-04-03

Review 6.  Management of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approach.

Authors:  Donald McCorquodale; Evan M Pucillo; Nicholas E Johnson
Journal:  J Multidiscip Healthc       Date:  2016-01-19

7.  Length-dependent MRI of hereditary neuropathy with liability to pressure palsies.

Authors:  Michael Pridmore; Ryan Castoro; Megan Simmons McCollum; Hakmook Kang; Jun Li; Richard Dortch
Journal:  Ann Clin Transl Neurol       Date:  2019-12-24       Impact factor: 4.511

8.  Case Report: Early-Onset Charcot-Marie-Tooth 2N With Reversible White Matter Lesions Repeatedly Mimicked Stroke or Encephalitis.

Authors:  Huasheng Huang; Yu Zhang; Mingxiu Yang; Baorong Lian; Rui Guo; Liming Cao
Journal:  Front Pediatr       Date:  2022-07-13       Impact factor: 3.569

9.  A novel mouse model carrying a human cytoplasmic dynein mutation shows motor behavior deficits consistent with Charcot-Marie-Tooth type 2O disease.

Authors:  Thywill T Sabblah; Swaran Nandini; Aaron P Ledray; Julio Pasos; Jami L Conley Calderon; Rachal Love; Linda E King; Stephen J King
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.